Dr. Najah Abi-Gerges, Vice President of Research & Development at AnaBios, will present the first research study on the impact of late sodium current (INa,L) modulation on the excitation-contraction coupling in adult human primary cardiomyocytes. This data will demonstrate that these human cardiomyocytes (1) express functional INa,L, (2) can differentiate INa,L facilitators from inhibitors and (3) provide valuable assessment of novel INa,L inhibitors to prevent the occurrence of drug-induced pro-arrhythmia and aid in the development of dysrhythmia medications. In addition, this 60-minute webinar will present information about AnaBios’ unique human tissue platform and electrophysiological and imaging capabilities. We are the only CRO that procures ethically consented human organs from a vast donor network in the United States. We also perform physiological assays using the cells and tissues from these organs. Learn about the different types of human tissue and cell-based assays and how translational assays are impacting preclinical drug discovery.
Dr. Michael Hildebrand, associate professor of neuroscience at Carleton University, highlights his recent work aimed at bridging the translational divide between target identification in rodent models of chronic pain and direct clinical testing of candidate compounds in humans. His research team has developed a novel human spinal cord tissue model of pathological pain that parallels rodent in vivo and ex vivo pain models. Using these complementary approaches, Dr. Hildebrand and his team are identifying molecular determinants of spinal cord hyperexcitability that are conserved across species, and thus may inform the rational development of more effective therapeutics for chronic pain.
- Pro-arrhythmia & contractility risk
- Human primary atrial cells in atrial fibrillation drug discovery
- Advancing the understanding of heart failure and new therapies with human primary ventricular myocytes and tissues